Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

The firm decreased its portfolio allocation in REGN by 11.88% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,438K shares representing 3.25% ownership ...

Clearly, options traders are pricing in a big move for Regeneron Pharmaceuticals shares ... the hope for these traders is that the underlying stock does not move as much as originally expected.

Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...

REGENERON PHARMACEUTICALS INC (REGN) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 71% based on the firm’s underlying fundamentals and the ...

REGENERON PHARMACEUTICALS ($REGN) is expected to release its quarterly earnings data on Tuesday, February 4th before market open. Analysts are expecting revenue of ...

REGENERON PHARMACEUTICALS ($REGN) posted quarterly earnings results on Tuesday, February 4th. The company reported earnings of $12.07 per share, beating estimates of ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

REGN) saw new options begin trading this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the REGN options chain for the new March 21st ...

Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired ...

While Regeneron has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question ...